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Background: -blockers oﬀer the ﬁrst line therapy in congenital long QT syndrome
(LQTS), and are more eﬀective to prevent the cardiac event in LQTS type 1 than in type 2
or 3. In contrast, left cardiac sympathetic denervation (LCSD) was shown to be highly
eﬀective in patients refractory to -blockers. Total sympathetic ablation by LCSD indicates
the addititional involvement of -adrenoceptor-mediated pathway. In genotyped LQT2
patients, we therefore hypothesized that blockade of -adrenoceptor in addition to -
adrenoceptor by carvedilol could reduce cardiac events more eﬃciently than other types of
-blockers.
Methods and Results: The study population consisted of 51 genotyped LQT2 patients (18
males, 23 11 years old). They were divided into 2 groups (group 1: 43 patients treated with
selective -blockers, group 2: 8 patients with carvedilol) and retrospectively analyzed the
eﬃcacy of the respective -blocker therapy in suppressing cardiac events. Cardiac events
were observed in 11 patients of group 1 (26%) but none in group 2 during a follow-up period
of 83 80 months (P ¼ 0:098).
Conclusions: Carvedilol may be a potentially beneﬁcial therapy for genotyped LQT2
patients who are refractory to other  selective blockers.
(J Arrhythmia 2011; 27: 324–331)
Key words: Long QT syndrome, -blocker therapy, carvedilol, -adrenoceptor
Introduction
Long QT syndromes (LQTS) are heterogeneous
inherited ion channelopathies characterized by pro-
longed ventricular repolarization, syncope, ventric-
ular arrhythmias, and sudden cardiac death with
normal cardiac structure.1) Sympathetic activation
and arrhythmogenesis are uniquely associated with
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LQTS. For example, in LQTS type 1 (LQT1),
exercise produces the QT prolongation and subse-
quent arrhythmic episodes.2,3) -blockers are there-
fore routinely prescribed in symptomatic LQT1
patients and reported to prevent ﬁrst cardiac events
in 74–80% of patients.4,5) In contrast, in LQT2,
cardiac symptoms mainly develop at rest, while
sleeping or by auditory stimuli,6) and the eﬃcacy
of -blockers is limited compared to that in LQT1.
In a recent report7) with large cohort of LQT2, -
blocker use reduced the risk of ﬁrst cardiac events
by 63%, however it was associated with less
protection (29%) in the prevention of lethal cardiac
events.
As to the additional therapy for patients refractory
to -blockers, left cardiac sympathetic denervation
(LCSD) has been shown to be highly eﬀective.8,9)
Total sympathetic ablation by LCSD indicates the
additional involvement of -adrenoceptor-mediated
pathway. Labetalol, an 1-and non selective -
blocker, was reported to be eﬀective to suppress
cardiac events in LQTS, although patients in this
study were not genotyped.10) As an anecdotal case,
we experienced that a LQT2 patient (S871fs+31X)
whose repetitive syncope due to TdP was not
suppressed by propranolol (30mg per day), but
subsequent carvedilol (10mg per day), an 1-and
non selective -blocker, was fully eﬀective.
Indeed, the diﬀerence in response to -blockers
may result from the distinct sympathetic response of
IKs currents (encoded by KCNQ1 gene that under-
lines LQT111,12)) and IKr currents (encoded by
KCNH2 gene that underlines LQT213)), which are
both critically responsible for ventricular repolariza-
tion. We recently demonstrated both in CHO cells
and HL-1 cardiomyocytes that Kv 11.1 channels
encoded by KCNH2 are acutely downregulated
by 1-adrenergic stimulation.
14) In the presence of
reduced function with Kv11.1 mutants (Y43D and
K595E), additional 1-adrenergic stimulation led to
a further decrease in residual channel currents and
thereby producing an extreme delay in repolariza-
tion. Thus, 1-adrenoceptor blockade might serve as
a promising medication and improve the symptoms
in LQT2 patients. We therefore retrospectively
surveyed the eﬃcacy of carvedilol for suppressing
cardiac events compared to other -selective block-
ers in genotyped LQT2 patients.
Methods
Study population (Figure 1) and genetic analysis
The study cohort consisted of 82 LQT2 probands
and their 51 family members, who were referred as
inherited cardiac arrhythmia subjects from 36 in-
stitutes in Japan, and genotyped from June 1996 to
December 2009 in Shiga University of Medical
Science (Otsu) or Kyoto University Graduate School
of Medicine (Kyoto). The patients with LQT1, 3, 5,
6, 7 or compound mutations15) were excluded. In the
total of 133 LQT2 patients, the -blocker therapy
was introduced in 51 patients, which consisted of our
ﬁnal study population (Figure 1).
DNA sequence analyses of KCNQ1, KCNH2,
SCN5A, KCNE1, KCNE2, and KCNJ2 were per-
formed as described previously.16,17) Mutation
screening was performed using polymerase chain
reaction (PCR) or denatured high-performance liquid
chromatography analyses (dHPLC, WAVE system;
Transgenomic Inc., Omaha, NE, USA).18) For aber-
rant PCR products, DNA sequencing was then
conducted with a DNA sequencer (ABI 3130 DNA
Sequencer; Perkin Elmer, Foster City, CA, USA).
When a mutation was detected, the result was
Figure 1 Schematic representation of the positive-mutation carriers in this study.
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compared to >200 Japanese control subjects, and
single nucleotide polymorphisms were excluded
from this study.
The protocol for genetic analysis complied with
the Declaration of Helsinki and was approved by the
institutional ethics committees and performed under
their guidelines. All individuals or their guardians
gave written informed consent to genetic and clinical
data analyses.
Clinical characteristics
In 51 LQT2 patients receiving the -blocker
therapy, baseline clinical characteristics were col-
lected including age at diagnosis, age at the ﬁrst
cardiac event, age at -blocker therapy started, and
Schwartz score.19) With regard to family history, we
deﬁned it as positive if a subject had a family
member who had Schwartz score of 4. Triggers of
symptom were deﬁned as follows: 1) at rest/during
sleep, 2) arousal, 3) auditory stimuli, 4) pregnancy/
post delivery and 5) during exercise.
ECG parameters used for analyses were baseline
heart rate (HR) and QT intervals. Measurements
were performed in 3 successive sinus beats in lead II
(if not possible, in lead V5) and averaged. QT was
manually measured as the time interval between
QRS onset (Q) and the point at which the isoelectric
line intersected a tangential line drawn at the
maximal down slope of the positive T wave or the
upslope of the negative T wave (QT), and corrected
using Bazett’s formula.20)
LQTS-related cardiac events included unex-
plained syncope, aborted cardiac arrest requiring
cardiac resuscitation, appropriate ICD shock and
unexpected sudden death exclusive of a known cause
before age 45 years. Those data were compared
between the group treated with -selective blockers
and the group with carvedilol.
Treatment including -blocker therapy
The speciﬁc -blocker used, as well as dose, was
at the discretion of the treating physician. The
type and dose of -blocker used, cardiac event
rate on each -blocker, adjunctive therapy and
follow-up period were collected and compared
between the -selective blockers group and the
carvedilol group. If patients were treated with -
selective blockers and thereafter carvedilol due to
ineﬀective -blocker therapy, they were included
in the carvedilol group. Follow-up period was
calculated from the starting date of -blocker to
the day of a cardiac event. We excluded patients
from analysis who were non-compliant to a prescri-
bed -blocker.
Statistical analysis
Data were expressed as mean  standard devia-
tion (SD) for continuous variables. Comparisons
were performed by chi-square test for categorical
variables and t-test for continuous variables. The
Kaplan-Meier estimator was used to assess the time
to a ﬁrst event and the cumulative event rates by
groups were compared using the log-rank test. P <
0:05 was considered statistically signiﬁcant. The
statistical software used for the analyses was JMP
version 7.0.1 (SAS institute Inc., NC, USA).
Results
Characteristics of the study population
In our LQTS cohort, 133 patients from 82
unrelated families were identiﬁed as sole KCNH2
mutation carriers. In those LQT2 patients, 51
patients (46 probands and 5 family members)
received the -blocker therapy. To compare the
clinical characteristics, we divided the study pop-
ulation into 2 groups: the -selective blockers group
(43 patients, mean age at diagnosis 22 11 years)
and the carvedilol group (8 patients, mean age at
diagnosis 26 11 years) (Figure 1).
Table 1 shows the clinical characteristics of the
two groups. Regarding triggers of symptoms, sudden
arousal was more frequent in the carvedilol group
(P ¼ 0:0313). There was no statistical diﬀerence
between the two groups including age, gender,
Schwartz scores, ECG parameters and cardiac events
before therapy. Distribution of mutations was not
signiﬁcantly diﬀerent between the two groups.
Treatment
As an adjunctive therapy, -selective group
received mexiletine more frequently than the carve-
dilol group (10/43 -selective group vs. 0/8 carve-
dilol group, P ¼ 0:0473) (Table 1). Ten patients
(9/43 in the -selective group, 1/8 in the carvedilol
group) were implanted with an implantable cardi-
overter deﬁbrillator (ICD). No patients underwent
LCSD.
-Blocker therapy (Table 2)
The -blocker therapy was started at age of 19
12 (0–63) years in total, 17 11 years in the -
selective group and 26 12 years in the carvedilol
group, respectively (Table 1). The mean age of
carvedilol start was signiﬁcantly (P ¼ 0:0372) older
than that of -selective blockers. We experienced
three patients in whom -selective blockers ﬁrst
failed but subsequent carvedilol was successful to
prevent cardiac events. Those cases were included
J Arrhythmia Vol 27 No 4 2011
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into the carvedilol group because they recurred
shortly after -selective blocker treatment and the
period for carvedilol therapy was suﬃciently long.
-selective blockers used in 43 LQT2 patients were
atenolol in 7 patients (75:0 61:2mg, 25–200mg),
bisoprolol in 3 (4:2 1:2mg, 2.5–5.0mg), carteolol
in 1 (20mg), metoprolol in 5 (68:0 33:1mg, 30–
120mg), nadolol in 1 (60mg), and propranolol in
26 (34:0 13:3mg, 10–60mg). Eight patients were
treated with carvedilol (16:9 10:3mg, 5–40mg).
Unfortunately, we have no data of patients’ body
weight, and the data of mg per kg were not shown.
Cardiac events during follow-up
Mean follow-up durations without any cardiac
events after drug introduction were 84 86 months
in the -selective blocker group and 73 43 months
in the carvedilol group. Eleven patients (26%) had
cardiac events while receiving -blocker therapy, but
no one (0%) experienced arrhythmic episodes in the
carvedilol group (Table 3). Kaplan-Meier survival
curve showed a tendency of superior eﬃcacy of
carvedilol (P ¼ 0:098, log-rank test) (Figure 2).
Three of 11 recurrence cases had pore mutations
(27%), and four had non-missense mutations (36%),
Table 1 Clinical characteristics
All patients
n ¼ 51
-selective blockers
n ¼ 43
Carvedilol
n ¼ 8 P value
Demographics
Proband, n (%) 46 (90) 40 (93) 6 (75) N.S.
Male, n (%) 18 (35) 16 (37) 2 (25) N.S.
Age at diagnosis, mean SD, years 23 11 22 11 26 12 N.S.
Age at ﬁrst cardiac event, mean SD, years 15 10 14 9 18 10 N.S.
Age at -blocker started 19 12 17 11 26 12 0.0372

Schwartz score, mean SD 5:2 1:7 5:2 1:7 5:6 1:3 N.S.
Electrocardiogram
HR, mean SD, bpm 63 10 61 7 64 11 N.S.
QTc, mean SD, ms 515 63 513 62 525 65 N.S.
Location of mutation, n (%)
N terminal 10 (17) 8 (17) 2 (25) N.S.
C terminal 18 (35) 16 (37) 2 (25) N.S.
Pore 11 (22) 10 (23) 1 (13) N.S.
Trans membrane 12 (24) 9 (21) 3 (38) N.S.
Non-missense mutation, n (%) 22 (43) 17 (40) 5 (62) N.S.
Cardiac events before -blocker therapy
Syncope, presyncope, n (%) 48 (94) 40 (93) 8 (100) N.S.
Documented TdP, n (%) 26 (51) 22 (51) 4 (50) N.S.
Documented VF, n (%) 5 (10) 5 (12) 0 (0) N.S.
Trigger of symptoms
At rest, during sleep, n (%) 24 (50) 22 (55) 2 (25) N.S.
Arousal, n (%) 10 (20) 6 (15) 4 (50) 0.0313

Auditory stimuli, n (%) 7 (14) 6 (15) 1 (12) N.S.
Pregnancy, post delivery, n (%) 3 (6) 2 (5) 1 (13) N.S.
Exercise, n (%) 2 (4) 2 (5) 0 (0) N.S.
Adjunctive LQTS therapy (any time)
Mexiletine, n (%) 10 (20) 10 (23) 0 (0) 0.0473

Pacemaker, n (%) 0 0 0 N.S.
LCSD, n (%) 0 0 0 N.S.
ICD, n (%) 10 (20) 9 (21) 1 (13) N.S.
Follow-up duration after -blocker, month SD 83 80 84 86 73 43 N.S.

P < 0:05 vs -selective blocker group
TdP: Torsade de pointes, VF: ventricular ﬁbrillation, LCSD: left cardiac sympathetic denervation, ICD: implantable cardioverter
deﬁbrillator
Kimura H Carvedilol for long QT syndrome type 2
327
and therefore these incidences were not signiﬁcantly
diﬀerent irrespective of -selective blocker eﬀec-
tiveness.
Two of eleven patients (18%) in the -selective
blocker group experienced appropriate ICD shocks:
one patient treated with propranolol (30mg per day)
and another treated by nadolol (60mg per day), who
showed an electrical storm. In two patients with
ineﬀective propranolol therapy, recurrent syncope
was controlled by diazepam as an adjunctive
therapy.
Three of eight patients in the carvedilol group
were ﬁrst treated with propranolol, but experienced
recurrent cardiac events, and the treatment was
changed to carvedilol. In two cases, carvedilol was
introduced because it was longer acting than pro-
pranolol. In the one remaining case, carvedilol was
prescribed because of its additional -blocking
action.
Figure 3A shows a family tree showing a typical
case that was refractory to propranolol but success-
fully controlled by carvedilol. The proband was a
9-year-old girl (indicated by arrow in Figure 3A),
and genetic test identiﬁed a heterozygous KCNH2
mutation (S871fs+31X). She was diagnosed as long
QT syndrome at age of 6 years (12-lead ECG in
Figure 3B, QTc = 500ms) but remained asympto-
matic. At age 9, she had loss of consciousness twice
just after waking to an alarm clock in the morning.
Her Holter ECG (Figure 3C) revealed repetitive TdP
triggered by auditory stimuli, and she complained
of uncomfortable chest distress. Propranolol (30mg
per day) was then prescribed, but her clinical
complaints continued. Medication was ﬁnally
switched to carvedilol (10mg per day), which
completely relieved her symptoms though the drug
did not alter her QTc and HR. Her mother also
collapsed at the delivery of the proband at age of 32
and genetic test revealed the same KCNH2 mutation.
Carvedilol was also started to prescribe for this
proband’s mother.
Table 3 Cardiac events on -blocker therapy
-selective
blocker,
n ¼ 43
Carvedilol
n ¼ 8
Total of cardiac events, pt n, (%) 11 (26) 0
Syncope, n, (%) 11 (26) 0
Documented TdP, n, (%) 4 (9) 0
Aborted sudden
cardiac arrest, n, (%) 1 (2) 0
Appropriate ICD shock, n, (%) 2 (5) 0
TdP: Torsade de pointes, ICD: implantable cardioverter
deﬁbrillator
Figure 2 Kaplan-Meier analysis of cumulative car-
diac event-free survival from each -blocker therapy
started to 150 months.
Table 2 Dose and variety of -blockers
n, (%) Dose per day,
mean SD (range)
-selective blockers, n ¼ 43
Atenolol 7 (14) 75:0 61:2 (25–200)mg
Bisoprolol 3 (6) 4:2 1:2 (2.5–5)mg
Carteolol 1 (2) 20 0mg
Metoprolol 5 (10) 68:0 33:1 (30–120)mg
Nadolol 1 (2) 60 0mg
Propranolol 26 (51) 34:0 13:3 (10–60)mg
Non-selective - and 1-blocker, n ¼ 8
Carvedilol 8 (16) 16:9 10:3 (5–40)mg
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Discussion
In our study cohort of LQT2 patients, carvedilol,
which blocks both 1-and -adrenoceptors, was
more eﬀective than other -selective blockers in
suppressing cardiac events without major complica-
tions. As widely recognized, -blockers are the ﬁrst
line therapy for the prevention of cardiac events in
the long QT syndrome. The studies on genotype-
phenotype relationships of the syndrome in the last
decade, however, have conﬁrmed that -blockers are
most eﬀective in LQT1, but less in LQT2 or LQT3
patients.4) For example in 2004, Priori and collea-
gues21) reported nearly a 3-fold increase in the risk of
cardiac events during -blocker treatment in LQT2
as compared to LQT1 patients, although there is a
conﬂicting report by Goldenberg and colleagues.22)
They demonstrated that a -blocker was suﬃciently
eﬀective in high risk patients with both LQT1 and
LQT2. As to 1-and -blockers, there are a few
reports which demonstrated that 1-and -adoreno-
ceptor blockade was eﬀective to shorten QTc
interval in the upright position before exercise and
early recovery phase after exercise,23) or suppress
arrhythmic events in LQTS with unknown geno-
type.10) There is another suggestive study of
Khositseth et al24) that phenylephrine-induced bra-
dycardia increased transmural dispersion of repola-
rization (TDR) in symptomatic LQT2 but not in
LQT1 patients. Therefore, 1-adrenoceptor blockade
(in addition to -adrenoceptor blockade) in LQT2
patients may actually lead to suppression of QT
prolongation and/or TDR, and eventually TdP. The
results in the present study were in line with the
above-mentioned hypothesis, and carvedilol actually
appeared to be beneﬁcial in suppressing cardiac
events in LQT2.
As Moss et al. reported in 1971,25) LCSD oﬀers an
alternative therapy to block sympathetic activation
for LQTS patients without reducing heart rate.
Antiarrhythmic action of LCSD is due largely to
the electrophysiological consequences of reduced
release of norepinephrine at the ventricular level and
includes prevention/suppression of early afterdepo-
larization (EAD). Although it does not entirely
control all cardiac events, the operation signiﬁcantly
reduces the number of symptoms and ICD shocks.9)
As the LCSD suppresses both -and -adrenergic
A B
C Ch1
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Ch3
I
II
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aVF
Figure 3 A typical case that was refractory to propranolol but controlled by carvedilol.
A. A pedigree of KCNH2-S871fs+31X. Circle indicates female, square indicates male. Closed symbol indicates mutation positive
subject. Black arrow indicates proband of this family, a 9-year-old girl. B. 12 lead ECG at resting state of proband. QTc = 500msec (V5).
C. A Holter ECG of proband. TdP was detected during an episode of syncope triggered by alarm clock early in the morning. Left panel:
just before the TdP. Right panel: TdP following left panel.
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contribution of sympathetic control, blockade of
1-adrenoceptors in addition to -adrenoceptors by
medication would also be useful to suppress the
severe form of cardiac events.
More recently, we reported that 1-adrenergic
stimulation acutely reduced Kv 11.1 channel activ-
ities via membrane PIP2 pathway.
14) Sudden 1-
adrenoceptor-mediated reduction in IKr at a lower
HR (for example, during sleep) would act addition-
ally to prolong action potential durations and may
enhance inward current through Na/Ca exchanger,
both contributing to the occurrence of EAD.26) These
observations may partially explain why sudden
auditory stimulation by an alarm clock induces
cardiac events in LQT2 patients.6) In this connection,
more recently Kim and colleagues27) demonstrated in
a large cohort of genotyped LQT2 patients that -
blockers were less eﬀective in patients with arousal
or non-exercise triggered events than those with
exercise triggered events to prevent the recurrence.
Although they did not mention the detailed species
of -blockers used for their patients, in our cohort,
11 recurrence cases in spite of -selective blockers
were all triggered by arousal or in a non-exercise
resting state, and carvedilol prevented the cardiac
event in three who were initially refractory to
propranolol.
Study limitations
Because this study was conducted in a retrospec-
tive manner, we were not able to adjust the selection
of patients between the two groups. Our study cohort
consisted of a relatively small number of LQT2
patients. In the carvedilol group, there were no
recurrent cases, which made further statistical analy-
ses, such as multivariate correlation study, diﬃcult.
A further study with a larger number of patients will
be awaited. In conclusion, in our genotyped LQT2
cohort, carvedilol was eﬀective to suppress cardiac
events, whereas 26% of the patients treated with
other -selective blockers experienced cardiac
events, suggesting that the simultaneous blockade
of 1-adrenoceptors may oﬀer an additional therapy
for LQT2 patient with non-exercise triggers.
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